While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

We recently published Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings. Gilead Sciences Inc (NASDAQ:GILD) is one of ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.

Biopharmaceutical company Gilead Sciences (GILD) has recently garnered significant attention from Wall Street, with analysts setting ambitious price targets, including a notable $105 target. This ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.

Despite challenges, Gilead Sciences sees a path to sustained growth thanks to a promising pipeline and strong existing products. Find out why GILD stock is a Buy.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing ...

Check out the latest Gilead Sciences Inc. (GILD) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.